Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Wednesday, December 5, 2018

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Clin Cancer Res. 2018 Dec 01;24(23):6098

Authors: Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC

PMID: 30510087 [PubMed - in process]



from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2rnLSEZ

No comments:

Post a Comment